

IMPLEMENTATION OF A PHARMACEUTICAL CARE PROCESS IN PATIENTS WITH ANEMIA AND CHRONIC KIDNEY DISEASE IN TREATMENT WITH ERYTHROPOIESIS STIMULATING FACTORS



M. Noguerol Cal, B.C. López Virtanen, J.A. Valdueza Beneítez, B. De la Nogal Fernández, S. Vázquez Troche, M. Rodríguez María, M.T. Sanz Lafuente, M. Oliveira Solís, A.D. López Villar, P. Cuevas Martínez. (Hospital el Bierzo, Pharmacy Hospital, Ponferrada, Spain).

BACKGROUND

We have implemented a process of pharmaceutical care in the pharmacy hospital in patients with anemia and chronic kidney disease in pre-dialysis patients in treatment with erythropoiesis stimulating factors (ESF), due to ongoing safety reviews and reports published in the last years.

PURPOSE

Assesing the follow-up of the pharmacy care process.

MATERIALS AND METHODS



We have put in place two transverse courts for 7 months in 2009 and 2010, including 100 % of sensitive patients.

The information was recorded in the Dispensation of Silicon® (Grifols) Program.

If Hemoglobin (Hb) levels were maintained between 10 and 12 g/dl, treatment was considered to be effective.

RESULTS

Year	2009	2010
Number of patients (N ^o p.)	100	79
N ^o p. insufficient monitoring of clinical information	31 (31%)	17 (21,5%)
Effective treatment	20	39



REASONS FOR INTERVENNING	NUMBER OF INTERVENTIONS /YEAR		RECOMENDATIONS
	2009	2010	
Hb increases more than 2 g/dl in 4 weeks	9	1	Changing dose or frequency of ESF administration
Hb >12 g/dl	29	8	
Hb ≥13 g/dl	0	3	Discontinuing drug, for safety.
Hb <11 g/dl to high doses*	34	8	Discontinuing, Inefficiency
Beginnings treatment Hb >10 g/dl	0	4	Not beginning

* Epoetin alfa doses > 300 Units/kg / week or darbepoetin alfa > 1,5 µg/kg/week. ‡= Hb levels (g/dl)

CONCLUSIONS

- > A decrease in the number of patients treated with ESF and the need of interventions was observed. (2010 vs 2009)
- > Accepted interventions were fewer also (2010 vs 2009), probably due to an increase in awareness when complying with the recommendations, motivated by the follow-up.
- > It was showed that medical checks were not too close, involving an insufficient monitoring of clinical data and difficulty to establish the effectiveness of many treatments.
- > This data will be reported to Nephrology Department in order to implement possible solutions.